Attendee search 

The Ontario Bioscience Innovation Organization (OBIO®) is focused on the development of an integrated health innovation economy for Ontario, Canada. The OBIO Capital Access Advisory Program (CAAPTM) is led by OBIO and a North American Steering Committee of life science venture capitalists and serial entrepreneurs to position selected high-potential bioscience companies for financing success. 

A unique not-for-profit, TEC Edmonton is a joint venture of the University of Alberta and the Edmonton Economic Development Corporation. TEC Edmonton helps technology entrepreneurs accelerate their growth. In addition to being the commercialization agent for University of Alberta technologies, TEC Edmonton operates Greater Edmonton's largest accelerator for early stage technology companies, including both university spinoffs and companies from the broader community. TEC Edmonton provides client services in four broad areas: Business development, funding and finance, technology commercialization and entrepreneur development. In 2015, TEC Edmonton was identified by the Swedish University Business Incubator (UBI) Index as the 4th best university business incubator in North America, and was also named Canadian "Incubator of the Year" at the 2014 Startup Canada Awards.

For more information, visit www.tecedmonton.com.

A unique not-for-profit, TEC Edmonton is a joint venture of the University of Alberta and the Edmonton Economic Development Corporation. TEC Edmonton helps technology entrepreneurs accelerate their growth. In addition to being the commercialization agent for University of Alberta technologies, TEC Edmonton operates Greater Edmonton's largest accelerator for early stage technology companies, including both university spinoffs and companies from the broader community. TEC Edmonton provides client services in four broad areas: Business development, funding and finance, technology commercialization and entrepreneur development. In 2015, TEC Edmonton was identified by the Swedish University Business Incubator (UBI) Index as the 4th best university business incubator in North America, and was also named Canadian "Incubator of the Year" at the 2014 Startup Canada Awards.

For more information, visit www.tecedmonton.com.

The Ontario Bioscience Innovation Organization (OBIO®) is focused on the development of an integrated health innovation economy for Ontario, Canada. The OBIO Capital Access Advisory Program (CAAPTM) is led by OBIO and a North American Steering Committee of life science venture capitalists and serial entrepreneurs to position selected high-potential bioscience companies for financing success. 

The Hospital for Sick Children (SickKids) is Canada’s largest, pediatric research hospital. Our history is one of research innovation. The Research Institute shares SickKids' vision of Healthier Children. A Better World.

SickKids Mission is:
◾Advancement of child health through global leadership in innovation, research and discovery.
◾Translation of research knowledge to benefit children and families everywhere.

Our research is supported by the generosity of donors who contribute to SickKids Foundation, as well as government agencies, non-profit foundations and companies and organizations that share our goals of improving child health outcomes.

Our research ranges from basic discovery research all the way to clinical care and is supported by state-of-the-art expertise, technologies and facilities. Our research activities are coordinated under seven major research programs, which range from basic science at the sub-molecular level, to organ systems, to population health. The seven programs cover the spectrum of child health from wellness and normal development to causes of diseases, diagnostics, treatments and therapies. Through these programs we cohesively and collaboratively bring together the more than 1,000 funded research projects and these internationally competitive and highly integrated research activities approach child health from all angles and disciplines.

Our scientists collaborate on hospital-wide interdisciplinary projects focusing on molecular therapies, cancer, brain, genetics, organs and chronic diseases and health care policies and practice. To support their research we provide our scientists with access to research expertise, state-of-the art equipment, technologies and services provided by core facilities and other resources.

The SickKids Industry Partnerships and Commercialization (IP&C) office is committed to ensuring that innovations developed at The Hospital for Sick Children have the widest impact possible. IP&C is a collaborative team of professionals with diverse expertise, including business development officers and analysts, communications and marketing professionals, license and royalty managers and intellectual property advisors and technology commercialization specialists.